BPC-157 for post-surgical recovery
BPC-157 after surgery — orthopedic and soft-tissue use cases, timing, surgeon clearance, NSAID interactions, and why it is not a substitute for PT.
Updated May 7, 2026 · 4 min read
BPC-157 after surgery is a common question, and the honest answer is: it might help, the pre-clinical record is suggestive, the post-op community reports are broadly positive, and none of it replaces talking to your surgeon first. Here is how to think about it without pretending the evidence is more settled than it is.
What surgeries it is reported for
The reported post-surgical use cases cluster in orthopedic and soft-tissue procedures:
- ACL reconstruction — graft incorporation and tendon harvest site recovery
- Meniscus repair — recovery from meniscectomy or repair
- Rotator cuff repair — tendon-to-bone healing
- Achilles repair — particularly after surgical re-attachment
- Labral repair (hip or shoulder)
- Hernia repair — soft tissue and abdominal wall recovery
- Soft-tissue cosmetic procedures — wound healing and reduced scarring
The mechanistic story across all of these is the same: BPC-157 is reported to promote angiogenesis and growth-factor signaling, which is exactly what newly repaired tissue needs to revascularize and remodel.
Talk to your surgeon first — really
This is not a throwaway disclaimer. There are real reasons your surgical team needs to know:
- Post-op infections can be masked or complicated by anything that modulates inflammation
- Bleeding risk with a peptide that promotes vascular activity is a genuine question for some surgeries
- Hardware integration in fusion or graft procedures has specific healing windows your surgeon owns
- Drug interactions with post-op medications (steroids, NSAIDs, anticoagulants) deserve a real conversation
If your surgeon does not know what BPC-157 is, that is not unusual — you can describe it as a research peptide reported to promote tissue healing, ask whether they have any concern, and accept their answer.
Pre-op vs. post-op timing
The community pattern splits roughly two ways:
| Approach | Reasoning | Reported pattern |
|---|---|---|
| Pre-loading (start before surgery) | Tissue priming before the controlled trauma | Start 1–2 weeks pre-op at 250 mcg/day |
| Post-op start (after the wound is closed) | Avoid any theoretical bleeding interaction | Start 5–14 days after surgery, surgeon-clearance-pending |
| Hybrid | Bracketing the surgical event | 1 week pre, pause around surgery, resume at 1–2 weeks post |
There is no clinical trial telling you which is best. Most surgeons who are aware of BPC-157 prefer the post-op start, on the conservative principle of changing one variable at a time around a planned procedure.
Reported post-op protocols
This is education, not a prescription. Common patterns:
- Soft-tissue / orthopedic post-op: 250–500 mcg daily SubQ for 4–6 weeks, often near (not into) the surgical area
- Tendon repair: 250 mcg twice daily for the first 4 weeks, then 250 mcg daily out to week 8–12
- General wound healing: 250 mcg daily for 2–4 weeks
Many users layer with TB-500 for tendon and ligament repairs, since the two peptides are reported to have complementary mechanisms.
NSAIDs and steroid interactions
A specific issue worth flagging:
- NSAIDs (ibuprofen, naproxen, diclofenac) suppress the inflammatory healing cascade. This is partly why surgeons often limit them post-op even without peptides in the picture. There is no clinical trial on how NSAIDs interact with BPC-157, but mechanistically they may blunt the same growth-factor signaling BPC-157 supports.
- Corticosteroid injections locally suppress healing in the tissue they are injected into. Running BPC-157 to support healing of a tissue you just steroid-injected is working against yourself.
- Anticoagulants (Eliquis, Xarelto, warfarin, heparin) are a separate question your prescriber should weigh. BPC-157 has no documented anticoagulant interaction in the literature, but absence of evidence is not evidence of safety.
Why BPC-157 is not a substitute for PT
The temptation post-op is to assume a peptide will do the work physical therapy does. It will not. Tissue remodels along the lines of mechanical load. Without progressive loading and movement, you grow back disorganized scar tissue regardless of how much growth-factor signaling is happening.
The best-reported outcomes pair BPC-157 with the rehab plan, not in place of it:
- Follow your post-op restrictions as written
- Hit your PT sessions and home program
- Use the peptide as an adjunct to recovery, not a shortcut around it
Wound and incision considerations
For incision recovery specifically:
- Do not inject BPC-157 directly through or into a fresh surgical wound
- Use a SubQ site away from the incision (abdomen is fine for nearly any non-abdominal surgery)
- Watch for any signs of infection at injection sites independently of the surgical site
Cancer caveat
BPC-157's angiogenic mechanism has theoretical cancer concerns. For most orthopedic surgeries this is not relevant, but if your procedure was oncology-related — tumor resection, sentinel node biopsy, mastectomy — running an angiogenic agent post-op is a conversation that has to happen with your oncology team, not a self-experiment.